1. Home
  2. VERU vs SURG Comparison

VERU vs SURG Comparison

Compare VERU & SURG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERU
  • SURG
  • Stock Information
  • Founded
  • VERU 1971
  • SURG 2006
  • Country
  • VERU United States
  • SURG United States
  • Employees
  • VERU N/A
  • SURG N/A
  • Industry
  • VERU Biotechnology: Pharmaceutical Preparations
  • SURG Advertising
  • Sector
  • VERU Health Care
  • SURG Consumer Discretionary
  • Exchange
  • VERU Nasdaq
  • SURG Nasdaq
  • Market Cap
  • VERU 54.6M
  • SURG 58.6M
  • IPO Year
  • VERU 1990
  • SURG N/A
  • Fundamental
  • Price
  • VERU $4.29
  • SURG $2.82
  • Analyst Decision
  • VERU Strong Buy
  • SURG Strong Buy
  • Analyst Count
  • VERU 3
  • SURG 1
  • Target Price
  • VERU $33.33
  • SURG $9.50
  • AVG Volume (30 Days)
  • VERU 158.4K
  • SURG 90.0K
  • Earning Date
  • VERU 08-12-2025
  • SURG 11-11-2025
  • Dividend Yield
  • VERU N/A
  • SURG N/A
  • EPS Growth
  • VERU N/A
  • SURG N/A
  • EPS
  • VERU N/A
  • SURG N/A
  • Revenue
  • VERU $16,886,419.00
  • SURG $36,461,935.00
  • Revenue This Year
  • VERU N/A
  • SURG $47.01
  • Revenue Next Year
  • VERU N/A
  • SURG $81.15
  • P/E Ratio
  • VERU N/A
  • SURG N/A
  • Revenue Growth
  • VERU 337.24
  • SURG N/A
  • 52 Week Low
  • VERU $2.64
  • SURG $1.05
  • 52 Week High
  • VERU $14.20
  • SURG $3.47
  • Technical
  • Relative Strength Index (RSI)
  • VERU 74.55
  • SURG 50.29
  • Support Level
  • VERU $3.75
  • SURG $2.51
  • Resistance Level
  • VERU $3.99
  • SURG $2.90
  • Average True Range (ATR)
  • VERU 0.24
  • SURG 0.14
  • MACD
  • VERU -0.01
  • SURG -0.01
  • Stochastic Oscillator
  • VERU 94.34
  • SURG 56.00

About VERU Veru Inc.

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

About SURG SurgePays Inc.

Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.

Share on Social Networks: